Düsseldorf, Nordrhein-Westfalen, Germany The fund was located in Europe if to be more exact in Germany. The leading representative office of defined Corporate Investor is situated in the Du00fcsseldorf.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the West Deutsche Landesbank Girozentrale, startups are often financed by Technomark Medical Ventures, Excalibur Fund Managers. The meaningful sponsors for the fund in investment in the same round are Technomark Medical Ventures, Temasek Holdings, Scottish Equity Partners. In the next rounds fund is usually obtained by Scottish Equity Partners, VC Fonds Technologie Berlin, Triathlon Medical Venture Partners.
Comparing to the other companies, this West Deutsche Landesbank Girozentrale performs on 21 percentage points more the average number of lead investments. The increased amount of exits for fund were in 2016. The important activity for fund was in 2001. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year.
For fund there is no match between the location of its establishment and the land of its numerous investments - United Kingdom. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline BioVex, Noxxon Pharma Among the most successful fund investment fields, there are Optical Communication, Semiconductor.
Related Funds
| Fund Name | Location |
| Archipelago Advisa Investment | Indonesia, Jawa Tengah, Surakarta |
| BHP | Australia, Melbourne, Victoria |
| Cleantech Open | California, Palo Alto, United States |
| Discount Capital | Israel, Tel Aviv, Tel Aviv District |
| DSL Capital | - |
| Gilbert Global Equity Partners | Jersey City, New Jersey, United States |
| Global Excel Management Inc. | Canada, Quebec, Sherbrooke |
| GW Holdings LLC | Arizona, Paradise Valley, United States |
| Hongyiyuan Touzi | China, Futian, Guangdong |
| Jennings Capital Inc | Alberta, Calgary, Canada |
| LabCorp | Burlington, North Carolina, United States |
| Leo Sophia | Japan, Tokyo |
| Merck Research Laboratories | Boston, Massachusetts, United States |
| National Cancer Institute | Bethesda, Maryland, United States |
| Partners Path Investments | New York, New York, United States |
| Primwest | Geneva, Geneve, Switzerland |
| Rhia Ventures | California, San Francisco, United States |
| Tuniu | China, Jiangsu, Nanjing |
| Waters Corporation | Massachusetts, Milford, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
BioVex | $23M | 06 Oct 2003 | United Kingdom, England, United Kingdom | ||
BioVex | $13M | 30 Jul 2001 | United Kingdom, England | ||
EndPoints | $7M | 23 Jan 2001 | Massachusetts, United States | ||
Noxxon Pharma | $23M | 15 Nov 2000 | Berlin |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
BioVex | $23M | 06 Oct 2003 | United Kingdom, England, United Kingdom | ||
BioVex | $13M | 30 Jul 2001 | United Kingdom, England | ||
EndPoints | $7M | 23 Jan 2001 | Massachusetts, United States | ||
Noxxon Pharma | $23M | 15 Nov 2000 | Berlin |
